Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127886851 | 12788685 | 1 | I | 20160919 | 20160928 | 20160928 | EXP | US-BAXTER-2016BAX050255 | BAXTER | BENSIMHON P, VILLABLANCA J, SENDER L, MATTAHAY K, PARK J, SEEGER R, LONDON W, YAP J, KREISSMAN S. PERIPHERAL BLOOD STEM CELL SUPPORT FOR MULTIPLE CYCLES OF DOSE INTENSIVE INDUCTION THERAPY IS FEASIBLE WITH LITTLE RISK OF TUMOR CONTAMINATION IN ADVANCED STAGE NEUROBLASTOMA: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP. PEDIATRIC BLOOD AND CANCER. 2010 JAN 01;54(4):596-602. | 36.00 | MON | M | Y | 14.50000 | KG | 20160928 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127886851 | 12788685 | 1 | PS | CYCLOPHOSPHAMIDE FOR INJECTION, USP | CYCLOPHOSPHAMIDE | 1 | Unknown | 2 GM/M2/DAY, DAY 0 AND 1 FOR 2 CYCLES | U | 40745 | POWDER FOR SOLUTION FOR INJECTION | ||||||||
| 127886851 | 12788685 | 2 | SS | CYCLOPHOSPHAMIDE FOR INJECTION, USP | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 2 G/M2/DAY, DAY 0 AND 1 FOR 3 CYCLES | U | 40745 | POWDER FOR SOLUTION FOR INJECTION | ||||||||
| 127886851 | 12788685 | 3 | SS | MESNEX | MESNA | 1 | Unknown | ON DAYS 1 AND 2 | U | 20855 | FILM-COATED TABLET | ||||||||
| 127886851 | 12788685 | 4 | SS | VINCRISTINE | VINCRISTINE | 1 | Intravenous drip | DAY 0 AND 1 FOR TWO CYCLES | U | 0 | |||||||||
| 127886851 | 12788685 | 5 | SS | DOXORUBICIN | DOXORUBICIN | 1 | Unknown | DAY 0 AND 1 FOR TWO CYCLES | U | 0 | |||||||||
| 127886851 | 12788685 | 6 | SS | G-CSF | GRANULOCYTE COLONY-STIMULATING FACTOR NOS | 1 | Unknown | U | 0 | ||||||||||
| 127886851 | 12788685 | 7 | SS | G-CSF | GRANULOCYTE COLONY-STIMULATING FACTOR NOS | 1 | Unknown | U | 0 | ||||||||||
| 127886851 | 12788685 | 8 | SS | G-CSF | GRANULOCYTE COLONY-STIMULATING FACTOR NOS | 1 | Unknown | U | 0 | ||||||||||
| 127886851 | 12788685 | 9 | SS | G-CSF | GRANULOCYTE COLONY-STIMULATING FACTOR NOS | 1 | Unknown | U | 0 | ||||||||||
| 127886851 | 12788685 | 10 | SS | G-CSF | GRANULOCYTE COLONY-STIMULATING FACTOR NOS | 1 | Unknown | U | 0 | ||||||||||
| 127886851 | 12788685 | 11 | SS | G-CSF | GRANULOCYTE COLONY-STIMULATING FACTOR NOS | 1 | Unknown | U | 0 | ||||||||||
| 127886851 | 12788685 | 12 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | DAY 0 AND 1 FOR THREE CYCLES | U | 0 | 800 | MG/M**2 | |||||||
| 127886851 | 12788685 | 13 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | ON DAY 0, 1 AND 2 FOR 3 CYCLES | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127886851 | 12788685 | 1 | Neuroblastoma |
| 127886851 | 12788685 | 3 | Neuroblastoma |
| 127886851 | 12788685 | 4 | Neuroblastoma |
| 127886851 | 12788685 | 5 | Neuroblastoma |
| 127886851 | 12788685 | 6 | Product used for unknown indication |
| 127886851 | 12788685 | 12 | Neuroblastoma |
| 127886851 | 12788685 | 13 | Neuroblastoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127886851 | 12788685 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127886851 | 12788685 | Haematotoxicity |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |